ADENOSINE

Post-LOE

adenosine

ANDAINJECTIONINJECTABLE
Approved
Jun 2004
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Mechanism of Action Adenosine slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome.…

Indications (1)

Clinical Trials (5)

NCT06672523Phase 1Recruiting

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

Started Mar 2025
8 enrolled
Advanced Solid Tumors With Homozygous MTAP Deletion
NCT06360354Phase 1Recruiting

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Started May 2024
350 enrolled
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
NCT04892875Phase 1Withdrawn

A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers

Started Dec 2023
NCT05975073Phase 1/2Active Not Recruiting

A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

Started Aug 2023
53 enrolled
MTAP-null Non-Small-Cell Lung CancerMTAP-null Solid Tumors
NCT05915442Phase 2Recruiting

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Started Jul 2023